743860
Last Update Posted: 2016-11-16
Recruiting has ended
All Genders accepted | 18 Years-65 Years |
20 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848
This study is designed to assess the pharmacokinetics of darapladib and its metabolites following single and 28 days of repeat dosing of darapladib.
Eligibility
Relevant conditions:
Atherosclerosis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov